Times News Network
A general view of the Kremlin, Red Square and St. Basil’s Cathedral in central Moscow. AFP via Getty Images Text size Russia’s first default on its foreign debt in more than 100 years is the latest sign that the sanctions levied against the country after the Ukraine invasion have consequences. But it’s probably not that … Read More “The Russian Default Is Less Worrisome Than It Appears. Keep Watching Oil.” »
Text size Pfizer’s investment in Valneva will help support development of Lyme disease program. AFP via Getty Images Pfizer has agreed to invest €90.5 million ($95.25 million) in an 8.1% stake in Valneva to boost the two companies’ development of a vaccine against Lyme disease. The U.S. pharmaceutical giant will buy Valneva (ticker: VALN.France) at … Read More “Pfizer To Buy 8.1% Stake In French Vaccines Company Valneva” »
Text size Morgan Stanley cut its price target on Apple stock. Dreamstime Morgan Stanley is preparing for a slowdown in consumer spending on tech hardware, slashing target prices on stocks across the sector, including Apple . The tech giant’s stock, however, might still be the best bet in the space despite losing a quarter of … Read More “Apple Stock Has Dropped 25%. This Analyst Says It’s Still the Best Bet in Tech.” »
After months of speculation, Apple AAPL, +0.34% finally unveiled its buy now, pay later deals this week, wading into an industry that has experienced explosive growth. But consumers should be careful about jumping into the service and first consider some of the potential pitfalls, observers say. Buy now, pay later – also known as “BNPL” … Read More “Apple offers ‘buy now, pay later’. 4 reasons to think twice before signing up” »
Customers at the Apple Store at the Grand Central Terminal in New York City earlier this year. Getty Images Text size As Apple preparing to upgrade its products, there are two distinct trends affecting the economy right now and they are both bad for technology stocks. On the one hand, there is runaway inflation, with … Read More “Apple needs to show some sparks as customers prefer services over things” »
If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have stock market values that are less than how much they have in cash. “The market says a quarter of these companies are literally worthless,” said Jefferies biotech analyst Michael … Read More “Biotechnology is in ‘a category 5 storm, the same as energy in 2020’ – why contradictory says the sector is a purchase” »
Text size Dreamstime The stock market was terribly close to ending Friday in a bear market, at least 20% from its peak in early January. Many investors would like to see it get there so Wall Street could put it aside and start the work of moving up. Mark Newton, head of technical strategy at … Read More “Shares are ready for a jump higher after the S&P 500 closes over the bear market” »
Text size A healthcare professional is preparing a dose of Nuvaxovid vaccine. Jeroen Jumelet / ANP / AFP via Getty Images Novavax the stock fell on Friday after receiving a sales equivalent rating – the first since December 2020 and the only one from Wall Street. Bank of America Securities analyst Alec Stranahan began coverage … Read More “Novavax receives a sales rating. It has a Covid vaccine problem, analysts say.” »
Text size Phillips 66 raised its stock dividend this week. David Paul Morris / Bloomberg Phillips 66 , Cardinal health , and Electronic art was among U.S. companies declaring dividend increases this week. Phillips 66 (ticker: PSX), a refinery, declared a quarterly dividend of 97 cents per share, an increase of 5 cents, or about … Read More “Phillips 66, Electronic Arts and 5 more companies that raised their dividends” »
Text size Mario Tama / Getty Images Pfizer said Tuesday that it has agreed to buy migraine drug maker Biohaven Pharmaceuticals for $ 11.6 billion in cash. Under the terms of the deal, Pfizer (ticker: PFE) will pay $ 148.50 for each Biohaven share, the company said in a statement. The price represents a premium … Read More “Pfizer to Buy Biohaven Pharmaceuticals for $ 11.6 Billion” »
